Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
AMPH Quote, Financials, Valuation and Earnings
Last price:
$26.84
Seasonality move
:
-3.24%
Day range:
$26.44 - $27.12
52-week range:
$20.39 - $39.56
Dividend yield:
0%
P/E ratio:
11.89x
P/S ratio:
1.83x
P/B ratio:
1.59x
Volume:
175.2K
Avg. volume:
406.8K
1-year change:
-29.95%
Market cap:
$1.2B
Revenue:
$732M
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$185.1M | $0.83 | 2.12% | 24.53% | $31.71 |
|
ALGN
Align Technology, Inc.
|
$976.3M | $2.41 | 3.68% | 112.55% | $179.80 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$130.5M | -$1.05 | -32.42% | -80.04% | $87.99 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 31.31% | 54.16% | $1,093.22 |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$180.2M | $0.82 | 12.33% | 60.84% | $61.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$26.81 | $31.71 | $1.2B | 11.89x | $0.00 | 0% | 1.83x |
|
ALGN
Align Technology, Inc.
|
$157.84 | $179.80 | $11.3B | 30.59x | $0.00 | 0% | 2.90x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$80.65 | $87.99 | $13.1B | -- | $0.00 | 0% | 13.73x |
|
LLY
Eli Lilly & Co.
|
$1,076.98 | $1,093.22 | $963.9B | 53.26x | $1.50 | 0.56% | 16.52x |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$51.77 | $61.33 | $3B | 41.17x | $0.00 | 0% | 4.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
45.82% | 0.709 | 53.17% | 2.07x |
|
ALGN
Align Technology, Inc.
|
2.97% | 1.305 | 1.34% | 1.08x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.444 | 19.43% | 2.51x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
3.87% | 0.900 | 1.55% | 1.37x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$95M | $25.3M | 7.98% | 14.9% | 13.2% | $47.2M |
|
ALGN
Align Technology, Inc.
|
$667.1M | $156.1M | 9.43% | 9.72% | 15.67% | $169M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$148.3M | -$61M | -1.78% | -1.84% | -31.77% | -$61.8M |
Amphastar Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AMPH or ALGN?
Align Technology, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 5.7%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Align Technology, Inc.'s return on equity of 9.72%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B ALGNAlign Technology, Inc.67% $0.78 $4.1B -
What do Analysts Say About AMPH or ALGN?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 18.29%. On the other hand Align Technology, Inc. has an analysts' consensus of $179.80 which suggests that it could grow by 13.91%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Align Technology, Inc., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Align Technology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 ALGNAlign Technology, Inc.7 8 0 -
Is AMPH or ALGN More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Align Technology, Inc. has a beta of 1.860, suggesting its more volatile than the S&P 500 by 85.974%.
-
Which is a Better Dividend Stock AMPH or ALGN?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Align Technology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or ALGN?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Align Technology, Inc. quarterly revenues of $995.7M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Align Technology, Inc.'s net income of $56.8M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.89x while Align Technology, Inc.'s PE ratio is 30.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.83x versus 2.90x for Align Technology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.83x 11.89x $191.8M $17.4M ALGNAlign Technology, Inc.2.90x 30.59x $995.7M $56.8M
-
Which has Higher Returns AMPH or CRMD?
CorMedix, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 49.9%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 18.29%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 CRMDCorMedix, Inc.4 0 0 -
Is AMPH or CRMD More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.89x while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.83x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.83x 11.89x $191.8M $17.4M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns AMPH or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -82.06%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About AMPH or IONS?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 18.29%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 9.1%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is AMPH or IONS More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.
-
Which is a Better Dividend Stock AMPH or IONS?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or IONS?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.89x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.83x versus 13.73x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.83x 11.89x $191.8M $17.4M IONSIonis Pharmaceuticals, Inc.13.73x -- $156.7M -$128.6M
-
Which has Higher Returns AMPH or LLY?
Eli Lilly & Co. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 31.72%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About AMPH or LLY?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 18.29%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.51%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 LLYEli Lilly & Co.18 7 0 -
Is AMPH or LLY More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock AMPH or LLY?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AMPH or LLY?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.89x while Eli Lilly & Co.'s PE ratio is 53.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.83x versus 16.52x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.83x 11.89x $191.8M $17.4M LLYEli Lilly & Co.16.52x 53.26x $17.6B $5.6B
-
Which has Higher Returns AMPH or SUPN?
Supernus Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -23.49%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B -
What do Analysts Say About AMPH or SUPN?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 18.29%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $61.33 which suggests that it could grow by 18.47%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 SUPNSupernus Pharmaceuticals, Inc.4 1 0 -
Is AMPH or SUPN More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.462%.
-
Which is a Better Dividend Stock AMPH or SUPN?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or SUPN?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.89x while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.83x versus 4.28x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.83x 11.89x $191.8M $17.4M SUPNSupernus Pharmaceuticals, Inc.4.28x 41.17x $192.1M -$45.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
